Results 261 to 270 of about 288,723 (312)

Metabolic syndrome worsens sarcopenia and reduces nutritional therapy benefits in advanced gastric cancer. [PDF]

Front Nutr
Xu L, Zhang X, Feng Y, Wong VKW, Yao W, Feng Y.   +5 more
europepmc   +1 more source

Explainable Machine Learning Model for Predicting Postoperative Survival in Patients With Locally Advanced Gastric Cancer. [PDF]

Cancer Med
Gong Z, Zhou L, He Y, Deng Y, Zhou J, Wang W, Yang Q, Pan J, Li Y, Yuan X, Ma M.   +10 more
europepmc   +1 more source

Management of locally advanced gastric cancer

The Lancet Oncology
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Immunotherapeutic advances in gastric cancer

Surgery Today, 2021
Advanced gastric cancers are responsible for overwhelming human suffering and death. Despite the development of combination chemotherapies, the survival rates of patients with gastric cancer remain unsatisfactory. Given the growing evidence of the benefits of immunotherapy as an alternative treatment for other cancers such as advanced melanoma, non ...
Akira, Yoneda, Tamotsu, Kuroki, Susumu, Eguchi   +2 more
openaire   +2 more sources

CHEMOTHERAPY OF ADVANCED GASTRIC CANCER

Australian and New Zealand Journal of Surgery, 1983
Twenty‐eight patients with inoperable or metastatic gastric cancer were treated with combination chemotherapy using 5‐fluorouracil, adriamycin and mitomycin‐C (FAM). Twenty‐one patients had measurable disease parameters and 57 per cent of these experienced a major regression of disease following chemotherapy.
P G, Gill, A M, Jones, R, Abbott
openaire   +2 more sources

Chemotherapy of advanced gastric cancer

Cancer Treatment Reviews, 2007
Gastric cancer is the second most frequent cancer in the world. Approximately 84% of patients with gastric cancer will have advanced disease and median survival of these patients without chemotherapy is only 3-4 months. "Classical" chemotherapy regimens, mainly CF (cisplatin plus infusional 5FU) and ECF (cisplatin plus infusional 5FU plus Epirubicin ...
Fernando, Rivera, M Eugenia, Vega-Villegas, Marta F, López-Brea   +2 more
openaire   +2 more sources

Advanced gastric cancer and prognosis

Virchows Archiv A Pathological Anatomy and Histopathology, 1985
The morphological features of 158 gastric carcinomas were analyzed in an attempt to identify patterns best correlated with prognosis. To this end, the depth of infiltration, vascular invasion, intra- and perineoplastic lymphocytic infiltrate, lymph node metastases and number of metastatic lymph nodes were evaluated according to the several ...
Pagnini CA, RUGGE, MASSIMO
openaire   +3 more sources

Management of advanced gastric cancer

Expert Review of Gastroenterology & Hepatology, 2012
The management of advanced gastric cancer has only evolved a little over the last 15 years: platinum and fluoropyrimidine chemotherapy remains the backbone of therapy with ongoing debate as to the benefit of triplet therapy with either an anthracycline or taxane.
Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Custem, E., Shah, M., Kang, Y., Tebbutt, N.   +8 more
openaire   +3 more sources

Docetaxel in advanced gastric cancer

Anti-Cancer Drugs, 2002
Standard chemotherapy for advanced gastric cancer remains undefined. Two of the most popular regimens-ECF [epirubicin-cisplatin-5-fluorouracil (5-FU)] and PELF (cisplatin-epirubicin-5-FU-leucovorin)-have been shown to be active, but each has limitations.
Daniel G, Haller, Jean-Louis, Misset
openaire   +2 more sources